Price$7.32-0.23 (-3.05%)
2026-03-042026-06-05
News · 26 weeks43-90%
2025-12-142026-06-07
Mix3090d
- SEC Filings15(50%)
- Insider9(30%)
- Other4(13%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- SECAmendment: SEC Form 10-K/A filed by Adicet Bio Inc.10-K/A - Adicet Bio, Inc. (0001720580) (Filer)
- PRAdicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceAdicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 2-4, 2026 in New York. Details of the event are as follows: Date: Thursday, June 4, 2026 Time: 7:35a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. i
- SECSEC Form S-8 POS filed by Adicet Bio Inc.S-8 POS - Adicet Bio, Inc. (0001720580) (Filer)
- SECSEC Form 10-Q filed by Adicet Bio Inc.10-Q - Adicet Bio, Inc. (0001720580) (Filer)
- SECAdicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adicet Bio, Inc. (0001720580) (Filer)
- PRAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesClinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients with a minimum of six months follow-up U.S. Food and Drug Administration (FDA) interaction to inform potential pivotal trial design for prula-cel expected in 2Q/2026 On track to submit regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) in 3Q/2026; enrollment expected to begin 4Q/2026, pending regulatory clearance Continued advancement of cell therapy programs and differentiated in vivo CAR-T platform targeting multiple indications
- ANALYSTJefferies resumed coverage on Adicet Bio with a new price targetJefferies resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $19.00
- INSIDERLarge owner Ra Capital Management, L.P. disposed of 250,000 shares (SEC Form 4)4 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECSEC Form DEFA14A filed by Adicet Bio Inc.DEFA14A - Adicet Bio, Inc. (0001720580) (Filer)
- SECSEC Form DEF 14A filed by Adicet Bio Inc.DEF 14A - Adicet Bio, Inc. (0001720580) (Filer)
- SECAdicet Bio Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Adicet Bio, Inc. (0001720580) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adicet Bio Inc.SCHEDULE 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ra Capital Management, L.P.3 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Adicet Bio Inc.SCHEDULE 13D/A - Adicet Bio, Inc. (0001720580) (Subject)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECSEC Form 144 filed by Adicet Bio Inc.144 - Adicet Bio, Inc. (0001720580) (Subject)
- SECSEC Form 144 filed by Adicet Bio Inc.144 - Adicet Bio, Inc. (0001720580) (Subject)
- SECSEC Form 144 filed by Adicet Bio Inc.144 - Adicet Bio, Inc. (0001720580) (Subject)
- INSIDERSEC Form 4 filed by Harvey Brian Nicholas4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Schor Chen4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Maltzman Julia D.4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Healey Don4 - Adicet Bio, Inc. (0001720580) (Issuer)
- INSIDERSEC Form 4 filed by Aftab Blake4 - Adicet Bio, Inc. (0001720580) (Issuer)
- SECSEC Form EFFECT filed by Adicet Bio Inc.EFFECT - Adicet Bio, Inc. (0001720580) (Filer)
ACET FAQ
7 questionsWhat does Adicet Bio Inc. do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which...Where does ACET stock trade?
Adicet Bio Inc. (ACET) is listed on NASDAQ.What sector and industry is ACET in?
Adicet Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adicet Bio Inc. go public?
Adicet Bio Inc. (ACET) completed its IPO in 2018.What are analysts saying about ACET?
Adicet Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1900.00 price target on 2026-05-05. Recent price targets range from $600.00 to $2800.00.What companies are similar to ACET?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACET side-by-side with any of them on Quantisnow.How can I track ACET on Quantisnow?
Quantisnow aggregates Adicet Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACET to receive live email and push alerts on every new disclosure.